Discussion
Topline results show a 26% response rate in a Phase 2 clinical trial evaluating melflufen (melphalan flufenamide)…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Discussion
Discussion
Despite some interruptions to melflufen‘s (melphalan flufenamide) clinical program due to the ongoing COVID-19 outbreak, Oncopeptides‘ application seeking its accelerated approval in…
Discussion
A novel genetic test could help identify people with multiple myeloma who are at highest risk of aggressive disease and unlikely to respond to standard…
Discussion
A combination of Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone failed to significantly extend the time to disease progression or death in people…
Discussion
Arcellx’s CART-ddBCMA — a CAR T-cell therapy targeting the BCMA protein — was granted orphan drug status by the U.S.
Discussion
The long-term survival of people with multiple myeloma following autologous stem cell transplant has steadily improved since 1997…
